Literature DB >> 24853878

Lysosomal storage diseases: Stem cell-based cell- and gene-therapy.

Seung U Kim.   

Abstract

Lysosomal storage diseases (LSDs) are caused by inborn genetic defects and most affected babies show pathology in the CNS. LSDs are caused by a specific inherited enzyme deficiency that results in accumulation of substrates in the lysosomes, distension of the organelles and subsequent cellular malfunction. Currently, no effective treatment is available for most of the LSDs, because the blood?brain barrier bars entry of enzyme preparations into the brain. Treatment for LSDs can be divided into those address symptoms or those address cause. At present, successful treatments for the LSDs are enzyme replacement therapy (ERT) and cell therapy. ERT is most successful in Gaucher disease and has been approved for Fabry disease, and mucopolysaccharidosis I (MPS I). In addition, ERT for Pompe disease, MPS II, MPS VI and MPS VII has been planned and awaiting approval for treatment. Limitations in ERT include need for life-long treatment, development of antibodies, and inability to cross blood brain barrier (BBB) resulting in failure to halt disease progression in the brain. Transplantation of hematopoietic stem cells (HSCs), bone marrow stem cells (BMSCs) and umbilical cord blood-derived stem cells (UCBSCs) offer effective but limited efficacy for patients suffering from Krabbe disease, MPS VII and adrenal leukodystrophy but in other LSDs they are ineffective. Intracranial/intracerebral transplantation of genetically modified stem cells as enzyme delivery system could bypass the BBB effectively and ensure release of therapeutically beneficial amount of enzymes to affected CNS lesion sites. For this reason, stem cell-based gene therapy is the most effective treatment for LSDs. In mouse models of LSDs, genetically modified neural stem cells encoding enzyme genes effectively decreased lysosomal storage, reduced pathology and extended life span of animals. Cell-based gene therapies for LSDs bridge the application of ERT and gene therapy and are important direction to pursue in the future.

Entities:  

Year:  2014        PMID: 24853878     DOI: 10.3727/096368914X681946

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  6 in total

Review 1.  Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.

Authors:  Je-Seong Won; Avtar K Singh; Inderjit Singh
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 2.  Stem Cell Therapy for the Central Nervous System in Lysosomal Storage Diseases.

Authors:  Faez Siddiqi; John H Wolfe
Journal:  Hum Gene Ther       Date:  2016-07-13       Impact factor: 5.695

Review 3.  Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis.

Authors:  Ryan D Geraets; Seung yon Koh; Michelle L Hastings; Tammy Kielian; David A Pearce; Jill M Weimer
Journal:  Orphanet J Rare Dis       Date:  2016-04-16       Impact factor: 4.123

4.  Spinal parenchymal occupation by neural stem cells after subpial delivery in adult immunodeficient rats.

Authors:  Martin Marsala; Kota Kamizato; Takahiro Tadokoro; Michael Navarro; Stefan Juhas; Jana Juhasova; Silvia Marsala; Hana Studenovska; Vladimir Proks; Tom Hazel; Karl Johe; Manabu Kakinohana; Shawn Driscoll; Thomas Glenn; Samuel Pfaff; Joseph Ciacci
Journal:  Stem Cells Transl Med       Date:  2019-12-04       Impact factor: 6.940

5.  Cell Transplantation Combined with Recombinant Collagen Peptides for the Treatment of Fabry Disease.

Authors:  Daisuke Kami; Masashi Yamanami; Takahiro Tsukimura; Hideki Maeda; Tadayasu Togawa; Hitoshi Sakuraba; Satoshi Gojo
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

6.  Genetically Modified Cell Transplantation Through Macroencapsulated Spheroids with Scaffolds to Treat Fabry Disease.

Authors:  Daisuke Kami; Yosuke Suzuki; Masashi Yamanami; Takahiro Tsukimura; Tadayasu Togawa; Hitoshi Sakuraba; Satoshi Gojo
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.